Saturday 17 October 2026 Export CAH’s income statement to Excel — free account

Cardinal Health, Inc.

Cardinal Health, Inc.’s revenue for fiscal 2026 (year ended June 2026) was $254.2 billion, up 14.2% from fiscal 2025. In the quarter to June 2026, revenue grew 5.84%, EPS grew 68.3%, free cash flow grew 10.9% and total debt rose 4.21%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for twenty-five consecutive years.

254.06 0.35 +0.14%

Follow CAH

Alert me

Market cap: $58.8B
P/E: 35.0×
Fwd P/E: 23.3×
Dividend yield: 0.81%
F-score: 7/9
Altman Z: 5.09
Beneish M: −2.74
Dividend safety: 86/100

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Impairment Aug 11, 2026

All filings →

Insider Decisions trades per month

Total sells 61.62

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	3	—	—	—	—	—	7	—	—

Insider Ownership 2.12%

Capital & Financial Ratios $m

Market Cap 58,750.00

Revenue 254,248.00

Net Income 1,705.00

Free Cash Flow 4,556.00

Net Debt 4,030.00

Current Ratio 0.88

Debt/Equity (3.26)

P/E ratio 34.99

Fwd P/E 23.30

P/S ratio 0.24

P/B ratio 0.00

Past 5Y EPS Growth 28.30%

This Y EPS Growth 11.38%

Next Y EPS Growth 12.22%

Next Y revenue growth 4.53%

Next 5Y EPS Growth 11.45%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/E against its own 10 years 79.37%

10-year low 10-year high

P/S against its own 10 years 98.23%

10-year low 10-year high

EV/Sales against its own 10 years 97.01%

10-year low 10-year high

EV/FCF against its own 10 years 69.17%

10-year low 10-year high

Dividends

Payout Ratio 0.28

Annual Dividend Rate 2.05

Annual Dividend Yield 0.81%

	total	individual payouts
2029	Powerpack
2028	Powerpack
2027	Powerpack
2026	2.05	0.51 0.51 0.52 0.52
2025	2.03	0.51 0.51 0.51 0.51
2024	1.51	0.50 0.51 0.51
2023	2.00	0.50 0.50 0.50 0.50
2022	1.98	0.49 0.50 0.50 0.50
2021	1.96	0.49 0.49 0.49 0.49
2020	1.94	0.48 0.49 0.49 0.49
2019	1.92	0.48 0.48 0.48 0.48
2018	1.89	0.46 0.48 0.48 0.48
2017	1.84	0.45 0.46 0.46 0.46
2016	1.73	0.39 0.45 0.45 0.45

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	2026
Cash	4,076	5,133	3,874	4,856
Receivables	11,108	12,084	13,242	13,815
Inventory	16,119	14,957	16,831	17,297
Other	140	47	12	21
	33,737	34,884	36,373	38,753

	2023	2024	2025	2026
Payables	29,934	31,759	34,713	38,283
ST’ Debt	792	434	550	1,882
Other	42	—	—	—
	33,740	35,640	38,897	43,904

Compound Annual Growth %

	10y	5y	3y
Sales	7.66%	9.37%	7.44%
Cash Flow	5.70%	16.33%	22.08%
Earnings	1.85%	22.91%	73.18%
Book Value	0.00%	0.00%	0.00%

Revenue $m

	Sep	Dec	Mar	Jun	Year
’26	—	—	—	—	—
’26	64,009	65,627	60,940	63,672	254,248
’25	52,277	55,264	54,878	60,159	222,578
’24	54,650	57,442	54,868	59,867	226,827
’23	49,603	51,469	50,487	53,420	204,979
’22	43,968	45,457	44,836	47,065	181,326
’21	39,065	41,541	39,275	42,586	162,467

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Sep	Dec	Mar	Jun	Year
’26	—	—	—	—	—
’26	973	686	1,823	1,692	5,174
’25	(1,647)	(396)	2,920	1,520	2,397
’24	528	1,179	(27)	2,082	3,762
’23	23	597	1,361	863	2,844
’22	(646)	1,195	(419)	3,045	3,175
’21	270	1,217	277	665	2,429

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Sep	Dec	Mar	Jun	Year
’26	—	—	—	—	—
’26	865	586	1,677	1,428	4,556
’25	(1,737)	(495)	2,797	1,288	1,853
’24	437	1,066	(131)	1,891	3,263
’23	(45)	512	1,252	644	2,363
’22	(713)	1,121	(490)	2,901	2,819
’21	192	1,121	177	539	2,029

Fiscal quarters ending in the months shown.

EPS $

	Sep	Dec	Mar	Jun	Year
’26	—	—	—	—	—
’26	1.88	1.97	1.69	1.69	7.23
’25	1.70	1.65	2.10	1.00	6.45
’24	(0.04)	1.43	1.05	0.96	3.45
’23	0.40	(0.50)	1.34	(0.25)	1.00
’22	0.94	0.17	(5.05)	0.50	(3.35)
’21	(0.86)	2.13	0.40	0.40	2.08

Fiscal quarters ending in the months shown.

Group	Line	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027e
Price, $
Price, $	Low	54.66	42.17	41.03	39.05	45.85	48.42	68.53	93.17	117.53	180.45	Analyst estimates 2027–2029 Powerpack
	High	84.88	75.75	56.88	60.69	62.96	81.57	108.85	126.23	214.93	258.30
People
People	Employees	28,000	32,300	31,000	30,000	47,300	46,500	48,000	48,900	57,700	63,900
	Revenue/emp, $m	4.64	4.24	4.69	5.10	3.43	3.90	4.27	4.64	3.86	3.98
Income, $m
Income, $m	Revenue	129,976	136,809	145,534	152,922	162,467	181,326	204,979	226,827	222,578	254,248
	Gross margin, %	5.03	5.25	4.70	4.49	4.17	3.58	3.35	3.27	3.67	3.84
	EBT	1,924	(228)	1,751	(3,772)	323	(784)	663	1,201	2,101	2,174
	EBT margin, %	1.48	(0.17)	1.20	(2.47)	0.20	(0.43)	0.32	0.53	0.94	0.86
	Net income	1,294	259	1,365	(3,693)	612	(937)	331	853	1,569	1,705
	Depreciation	717	1,032	1,000	913	783	692	692	710	790	956
Per share, $
Per share, $	Revenue	410.02	437.09	485.11	521.92	556.39	649.91	785.36	925.82	923.56	1,077.32
	Earnings	4.06	0.82	4.55	(12.61)	2.09	(3.35)	1.00	3.48	6.48	7.27
	Cash flow	3.74	8.84	9.07	6.69	8.32	11.38	10.90	15.36	9.95	21.92
	Capex	(1.22)	(1.23)	(1.09)	(1.27)	(1.37)	(1.28)	(1.84)	(2.04)	(2.26)	(2.62)
	Free cash flow	2.51	7.62	7.98	5.42	6.95	10.10	9.05	13.32	7.69	19.31
	Book value	21.54	19.36	21.10	6.12	6.14	(2.53)	(11.33)	(13.11)	(10.93)	(11.54)
	Shares, m	317	313	300	293	292	279	261	245	241	236
Valuation, ×
Valuation, ×	P/E	19.15	64.67	10.50	0.00	27.32	0.00	93.63	28.62	25.93	32.72
	P/S	0.19	0.11	0.10	0.10	0.10	0.08	0.12	0.11	0.18	0.22
	P/B	3.62	2.54	2.25	8.53	9.29	0.00	0.00	0.00	0.00	0.00
	EV/Sales	0.22	0.17	0.14	0.13	0.12	0.08	0.12	0.11	0.20	0.24
	EV/FCF	35.40	9.49	8.26	12.16	9.61	5.39	10.71	7.33	24.36	13.19
Cash, $m
Cash, $m	Operating cash flow	1,184	2,768	2,722	1,960	2,429	3,175	2,844	3,762	2,397	5,174
	Capex	(387)	(384)	(328)	(373)	(400)	(356)	(481)	(499)	(544)	(618)
	Free cash flow	797	2,384	2,394	1,587	2,029	2,819	2,363	3,263	1,853	4,556
Balance, $m
Balance, $m	Working capital	7,124	1,660	1,638	2,325	3,424	2,385	(3)	(756)	(2,524)	(5,151)
	Total debt	10,395	9,013	8,031	6,775	6,236	5,315	4,701	5,092	8,527	8,886
	Net debt	3,516	7,250	5,500	4,004	2,829	598	625	(41)	4,653	4,030
	Shareholders’ equity	6,828	6,059	6,330	1,792	1,794	(706)	(2,957)	(3,212)	(2,634)	(2,724)
Returns, %
Returns, %	ROA	3.47	0.64	3.37	(9.04)	1.43	(2.12)	0.76	1.93	3.18	3.10
	ROIC	12.81	0.59	10.88	(44.19)	6.38	0.00	0.00	0.00	70.42	125.05
	ROE	19.23	3.97	22.00	(91.01)	34.08	(172.43)	(18.02)	(27.62)	(53.40)	(63.98)

Negative figures in brackets.

All 10 years →

Fiscal years to Jun 2026 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
MCK McKesson Corporation	$116.4B	26.8×	18.3×	+7.72% (above 0%: growing)	−17.68% (below 0%: shrinking)	+66.40% (above 0%: growing)	3.50%	1.25%	Compare
COR Cencora, Inc.	$65.2B	25.2×	14.5×	+5.07% (above 0%: growing)	+11.27% (above 0%: growing)	+3,385.25% (above 0%: growing)	4.26%	1.32%	Compare
CAH Cardinal Health, Inc.	$58.8B	35.0×	23.3×	+5.84% (above 0%: growing)	+68.32% (above 0%: growing)	+10.87% (above 0%: growing)	4.02%	1.14%
HSIC Henry Schein, Inc.	$9.7B	25.0×	18.5×	+6.73% (above 0%: growing)	+16.90% (above 0%: growing)	+140.91% (above 0%: growing)	31.84%	4.95%	Compare
AHG Akso Health Group Sponsored ADR	$1.2B	— (loss-making)	— (loss-making)	+263.89% (above 0%: growing)	n/m	−12,975.04% (below 0%: shrinking)	0.00%	0.00%	Compare
FOCL FocalTherics	$154.8M	— (loss-making)	— (loss-making)	+38.85% (above 0%: growing)	n/m	+21.49% (above 0%: growing)	55.59%	(60.83%)	Compare
COSM Cosmos Health Inc.	$33.9M	— (loss-making)	25.1×	+28.76% (above 0%: growing)	n/m	+9.39% (above 0%: growing)	7.96%	(15.41%)	Compare
ACH Accendra Health, Inc.	$20.1M	— (loss-making)	— (loss-making)	−10.07% (below 0%: shrinking)	n/m	−1,624.82% (below 0%: shrinking)	42.95%	(5.73%)	Compare
HKPD Cellyan Biotechnology Co., Ltd	$17.1M	—	—	—	—	−90.45% (below 0%: shrinking)	—	—	Compare
Median of peers	$652.4M	25.2×	18.4×	+7.72%	+11.27%	+15.44%	7.96%	0.00%

All 11 Medical Distribution stocks →